| Omni Bridgeway Limited (OBL) ORDINARY FULLY PAID US PROHIBITED |
Financials |
$470 |
Half Year Report and Accounts at 31 December 2024
|
27 Feb 2025 9:04AM |
$1.240 |
$1.630 |
risen by
31.45%
|
|
OBL - Price-sensitive ASX Announcement
Full Release
Key Points
- Total income for the half-year was A$92.5 million.
- The Group reported a profit after tax of A$18.7 million.
- Investment proceeds reached A$236.2 million excluding fees.
- Fund 9 was launched as a continuation fund.
- A capital transaction with Ares Management was completed, enhancing liquidity.
- The Group has a strong pipeline of A$228 million in new investment opportunities.
- Total cash and receivables amounted to A$443.0 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| DUG Technology Ltd (DUG) ORDINARY FULLY PAID |
Information Technology |
$151 |
Appendix 4D and Interim Financial Report
|
27 Feb 2025 9:04AM |
$1.105 |
$1.125 |
risen by
1.81%
|
|
DUG - Price-sensitive ASX Announcement
Full Release
Key Points
- Total revenue reported at US$28.7 million for FY25-H1.
- Loss after tax of US$3.9 million for the period.
- Services order book grew to US$42.2 million by January 2025.
- Software revenue increased by 22% compared to FY24-H1.
- Successful restructuring initiatives to improve operational efficiency.
- Expansion of the R&D team with new talent hired.
- DUG's focus on innovative software and HPCaaS offerings.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Southern Cross Media Group Limited (SXL) ORDINARY FULLY PAID |
Communication Services |
$178 |
Agreement to sell remaining television assets to ADH
|
27 Feb 2025 9:04AM |
$0.660 |
$0.740 |
risen by
12.12%
|
|
SXL - Price-sensitive ASX Announcement
Full Release
Key Points
- SCA signed a binding proposal for selling television assets to ADH.
- The sale includes assets in Tasmania, Spencer Gulf, Broken Hill, Mt Isa, Darwin, and Remote Australia.
- The expected completion is in the coming weeks, subject to final documentation and conditions.
- Total proceeds from the sale are estimated between $19 million and $24 million.
- Upfront cash consideration is $3.75 million, with additional $2.6 million through transitional services.
- Proceeds will be used to reduce SCA's net debt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Thorney Opportunities Ltd (TOP) ORDINARY FULLY PAID |
Financials |
$115 |
Update - Notification of buy-back - TOP
|
27 Feb 2025 9:04AM |
$0.635 |
$0.650 |
risen by
2.36%
|
|
| Renascor Resources Limited (RNU) ORDINARY FULLY PAID |
Materials |
$170 |
Water Treatment Circuit to Deliver Low-Cost PSG
|
27 Feb 2025 9:04AM |
$0.050 |
$0.067 |
risen by
34%
|
|
RNU - Price-sensitive ASX Announcement
Full Release
Key Points
- Tests confirmed the effectiveness of water treatment in recycling reagents and treating process water.
- Assays from process streams were within acceptable ranges, supporting the recycling of reagents.
- Results highlight Renascor's HF-free purification process as a competitive alternative for battery-grade graphite.
- Technological readiness for advancing to detailed engineering of the PSG demonstration facility is confirmed.
- Commissioning of the PSG demonstration facility is expected to commence in Q3 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Maximus Resources Limited (MXR) ORDINARY FULLY PAID |
Materials |
$33 |
Change in substantial holding
|
27 Feb 2025 9:04AM |
$0.062 |
$0.077 |
risen by
24.19%
|
|
| Amotiv Limited (AOV) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,077 |
Update - Notification of buy-back - AOV
|
27 Feb 2025 9:03AM |
$9.960 |
$7.900 |
fallen by
20.68%
|
|
| Pepper Money Limited (PPM) ORDINARY FULLY PAID |
Financials |
$735 |
Appendix 4G
|
27 Feb 2025 9:03AM |
$1.375 |
$1.655 |
risen by
20.36%
|
|
| Pointsbet Holdings Limited (PBH) ORDINARY FULLY PAID |
Consumer Discretionary |
$372 |
PBH Response to BlueBet Announcement
|
27 Feb 2025 9:03AM |
$1.100 |
$1.120 |
risen by
1.82%
|
|
PBH - Price-sensitive ASX Announcement
Full Release
Key Points
- PointsBet received a proposal from BlueBet on 18 February 2025.
- The proposal suggests a value of $1.02-$1.09 per PointsBet share.
- PointsBet is under exclusivity arrangements with MIXI for a cash price of $1.06 per share.
- The PointsBet Board deemed the BlueBet proposal unlikely to lead to a superior offer.
- The proposal was unfunded and contingent on future capital raising.
- The PointsBet Board sought advice from financial and legal advisors before making its decision.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BETR Entertainment Limited (BBT) ORDINARY FULLY PAID |
Consumer Discretionary |
$357 |
PBH: PBH Response to BlueBet Announcement
|
27 Feb 2025 9:03AM |
$0.370 |
$0.365 |
fallen by
1.35%
|
|
BBT - Price-sensitive ASX Announcement
Full Release
Key Points
- PointsBet received a proposal from BlueBet on 18 February 2025.
- BlueBet's proposal was conditional and valued between $1.02 and $1.09 per share.
- PointsBet is under exclusivity with MIXI, Inc. for a cash offer of $1.06 per share.
- The PointsBet Board assessed the BlueBet proposal as unlikely to be superior.
- Concerns included financing risks and lack of detailed synergies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Rapid Lithium Limited (RLL) ORDINARY FULLY PAID |
Materials |
$4 |
Investor Presentation - Prophet River Ge-Ga Acquisition
|
27 Feb 2025 9:03AM |
$0.004 |
$0.003 |
fallen by
25%
|
|
| Amcor Plc (AMC) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$20,596 |
425 Ruling - Communication
|
27 Feb 2025 9:02AM |
$16.170 |
$14.250 |
fallen by
11.87%
|
|
| Amcor Plc (AMC) CDI 1:1 FOREIGN EXEMPT NYSE |
Materials |
$20,596 |
425 Ruling - Communication
|
27 Feb 2025 9:02AM |
$16.170 |
$14.250 |
fallen by
11.87%
|
|
| Rhythm Biosciences Limited (RHY) ORDINARY FULLY PAID |
Health Care |
$17 |
Investor Webinar
|
27 Feb 2025 9:01AM |
$0.094 |
$0.061 |
fallen by
35.11%
|
|
| Future Generation Global Limited (FGG) ORDINARY FULLY PAID |
Financials |
$567 |
Corporate Governance Statement
|
27 Feb 2025 9:01AM |
$1.470 |
$1.420 |
fallen by
3.40%
|
|
| Mesoblast Limited (MSB) ORDINARY FULLY PAID |
Health Care |
$2,153 |
Ryoncil Pricing Set and Available This Quarter
|
27 Feb 2025 9:01AM |
$2.460 |
$1.685 |
fallen by
31.50%
|
|
MSB - Price-sensitive ASX Announcement
Full Release
Key Points
- Ryoncil® will be available shortly for pediatric SR-aGvHD patients.
- The product has shown long-term survival benefits in high-risk patients.
- Ryoncil® is priced at $194,000 per infusion.
- Mesoblast is implementing financial assistance programs to ensure patient access.
- The company is collaborating with major transplant centers for distribution.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Thorney Technologies Ltd (TEK) ORDINARY FULLY PAID |
Financials |
$43 |
Update - Notification of buy-back - TEK
|
27 Feb 2025 9:00AM |
$0.130 |
$0.115 |
fallen by
11.54%
|
|
| Australian Clinical Labs Limited (ACL) ORDINARY FULLY PAID |
Health Care |
$609 |
Update - Notification of buy-back - ACL
|
27 Feb 2025 9:00AM |
$3.270 |
$3.080 |
fallen by
5.81%
|
|
| Djerriwarrh Investments Limited (DJW) ORDINARY FULLY PAID |
Financials |
$808 |
Update - Notification of buy-back - DJW
|
27 Feb 2025 9:00AM |
$3.090 |
$3.070 |
fallen by
0.65%
|
|
| Imugene Limited (IMU) ORDINARY FULLY PAID |
Health Care |
$127 |
Imugene Granted India Patent for Oncolytic Virotherapy CF33
|
27 Feb 2025 8:59AM |
$0.036 |
$0.017 |
fallen by
52.78%
|
|
IMU - Price-sensitive ASX Announcement
Full Release
Key Points
- CF33 patent granted in India, further strengthening global intellectual property protection
- Patent provides method of composition and method of use protection until 2037
- The term of this patent is 20 years from the filing date of 9 August 2017
- This patent adds to patent protection in the United States and Japan
- CF33 is a chimeric vaccinia poxvirus developed by Professor Yuman Fong
- Oncolytic viruses selectively target and destroy cancer cells while stimulating the immune system
- Imugene is committed to advancing its oncolytic virotherapy pipeline
- The grant of this patent is a significant step in expanding global protection for CF33
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ARN Media Limited (A1N) ORDINARY FULLY PAID |
Communication Services |
$164 |
Corporate Governance Statement
|
27 Feb 2025 8:58AM |
$0.620 |
$0.525 |
fallen by
15.32%
|
|
| ARN Media Limited (A1N) ORDINARY FULLY PAID |
Communication Services |
$164 |
Appendix 4G Corporate Governance
|
27 Feb 2025 8:58AM |
$0.620 |
$0.525 |
fallen by
15.32%
|
|
| Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID |
Health Care |
$8,683 |
App 3Y Change in Director Interests - C Behrenbruch
|
27 Feb 2025 8:58AM |
$31.000 |
$25.680 |
fallen by
17.16%
|
|
| Beston Global Food Company Limited (BFC) ORDINARY FULLY PAID |
Consumer Staple |
$6 |
Trading Update - Appointment of liquidators
|
27 Feb 2025 8:58AM |
$0.003 |
$0.003 |
fallen by
0%
|
|
| Cochlear Limited (COH) ORDINARY FULLY PAID |
Health Care |
$17,809 |
Update - Notification of buy-back - COH
|
27 Feb 2025 8:57AM |
$265.510 |
$272.320 |
risen by
2.56%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
